Hemostatic system in patients with endometrial hyperplasia and the risk of venous thrombosis: А literature review

Abstract

While treating patients with endometrial hyperplasia, the physician may face both bleeding and thrombotic complications, particularly, during hormonal or surgical treatment, which significantly increases the risk of these complications. In addition, thrombotic complications in gynecological patients may result from congenital or acquired thrombophilia, blood flow disorders (blood stasis), and vascular wall damage, that is, the classic Virchow triad.

This study aimed to review the recent scientific literature on the peculiarities of the blood coagulation system in patients with endometrial hyperplasia.

The review reflects the results of studies conducted by Russian and foreign authors on the status of the blood coagulation system in patients with endometrial hyperplasia. The features of vascular, thrombocytic, plasma (procoagulant and anticoagulant), and fibrinolytic elements of hemostasis in these patients are considered. The data from the literature on the state of hemostasis before treatment and following hormone therapy and surgical treatment are presented. Moreover, the data of some studies on the genetic features of the hemostatic system in patients with endometrial hyperplasia are summarized. An analysis of the literature indicates the need for a careful choice of drugs and methods of treatment of these patients to avoid venous thromboembolic complications.

Keywords

endometrial hyperplasia / abnormal uterine bleeding / blood coagulation system / vascular-thrombocytic, coagulant, anticoagulant, and fibrinolytic elements of hemostasis / hemostasis-related gene polymorphism

References

[1] Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020;76(1):151–156. doi: 10.1111/his.13977

[2] Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours // Histopathology. 2020. Vol. 76, N 1. P. 151–156. doi: 10.1111/his.13977

[3] Salamova KK, Saprykina LV, Ramazanova AM, et al. Clinical characteristics of women with endometrial hyperplasia. Russian Journal of Woman and Child Health. 2021;4(2):124–129. (In Russ). doi: 10.32364/2618-8430-2021-4-2-124-129

[4] Саламова К.К., Сапрыкина Л.В., Рамазанова А.М., Мильдзихова З.Т., Столярова Е.В. Клинические особенности пациенток с гиперпластическими процессами эндометрия // Русский медицинский журнал. Мать и дитя. 2021. № 2. C. 124–129 doi: 10.32364/2618-8430-2021-4-2-124-129

[5] Ozolinja LA, Lapina IA. Rational approaches to the prevention of vascular complications in patients with endometrial hyperplasia. Gynecology. 2014;16(3):53–56 (In Russ).

[6] Озолиня Л.А., Лапина И.А. Рациональные подходы к профилактике сосудистых осложнений у пациенток с гиперпластическими процессами эндометрия // Гинекология. 2014. Т. 16, № 3. С. 53–57.

[7] Ozolinya LA, Kerchelaeva SB, Lapina IA, Makarov OV. Venous thromboembolic complications in obstetrics and gynecology. 2nd ed., revis. and expand. Moscow: GEOTAR-Media; 2020. 288 p. (In Russ). doi: 10.33029/9704-5651-4-VTO-2020-1-288 5.

[8] Озолиня Л.А., Керчелаева С.Б., Лапина И.А., Макаров О.В. Венозные тромбоэмболические осложнения в акушерстве и гинекологии. 2-е издание, испр. и доп. Москва : ГЭОТАР-Медиа, 2020. 288 с. doi: 10.33029/9704-5651-4-VTO-2020-1-288

[9] Cakmak B, Gulucu S, Aliyev N, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios in endometrial hyperplasia. Obstet Gynecol Sci. 2015;58(2):157–161. doi: 10.5468/ogs.2015.58.2.157

[10] Cakmak B., Gulucu S, Aliyev N, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios in endometrial hyperplasia // Obstet Gynecol Sci. 2015. Vol. 58, N 2. P. 157–161 doi: 10.5468/ogs.2015.58.2.157

[11] Karateke A, Kaplanoglu M, Baloglu A. Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer. Asian Pac J Cancer Prev. 2015;16(12):4905–4908. doi: 10.7314/apjcp.2015.16.12.4905

[12] Karateke A., Kaplanoglu M., Baloglu A. Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer // Asian Pac J Cancer Prev. 2015. Vol. 16, N 12. P. 4905–4908. doi: 10.7314/apjcp.2015.16.12.4905

[13] Yayla Abide C, Bostanci Ergen E, Cogendez E, et al. Evaluation of complete blood count parameters to predict endometrial cancer. J Clin Lab Anal. 2018;32(6):e22438. doi: 10.1002/jcla.22438

[14] Yayla Abide C., Bostanci Ergen E., Cogendez E., et al. Evaluation of complete blood count parameters to predict endometrial cancer // J Clin Lab Anal. 2018. Vol. 32, N 6. P. e22438 doi: 10.1002/jcla.22438

[15] Acmaz G, Aksoy H, Unal D, et al. Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? Asian Pac J Cancer Prev. 2014;15(4):1689–1692. doi: 10.7314/apjcp.2014.15.4.1689

[16] Acmaz G., Aksoy H., Unal D., et al. Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? // Asian Pac J Cancer Prev. 2014. Vol. 15, N 4. P. 1689–1692. doi: 10.7314/apjcp.2014.15.4.1689

[17] Ural ÜM, Şehitoğlu İ, Tekin YB, Şahin FK. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2015;41(3):445–448. doi: 10.1111/jog.12536

[18] Ural Ü.M., Şehitoğlu İ., Tekin Y.B., Şahin F.K. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer // J Obstet Gynaecol Res. 2015. Vol. 41, N 3. P. 445–448. doi: 10.1111/jog.12536

[19] Senchuk A, Pokrovenko O. Modern aproaches to the choice of treatment of hyperplastic diseases of endo- and myometrium. Okhrana materinstva i detstva. 2013;(1):64–67. (In Russ).

[20] Сенчук А.Я., Покровенко О.Б. Современные подходы к выбору метода лечения гиперпластических заболеваний эндомиометрия // Охрана материнства и детства. 2013. № 1(21). С. 64–67.

[21] Saidova RA, Fedina EV. Investigation of the hemostasis system in women of reproductive age with provisional diagnosis ― endometrial hyperplasia. Journal of New Medical Technologies, eEdition. 2006;13(3):55. (In Russ).

[22] Саидова Р.А., Федина Е.В. Исследование состояния системы гемостаза у женщин с подозрением на гиперпластические процессы эндометрия в репродуктивном периоде // Вестник новых медицинских технологий. 2006. Т. 13, № 3. С. 55.

[23] Fedina EV. Investigation of the hemostasis system for solving the problem of choosing tactics for managing patients with endometrial hyperplastic processes in the reproductive period. Siberian Journal of Oncology. 2007;(S1 suppl.):94–96. (In Russ).

[24] Федина Е.В. Исследование системы гемостаза для решения проблемы выбора тактики ведения больных с гиперпластическими процессами эндометрия в репродуктивном периоде // Сибирский онкологический журнал. 2007. № S1 (приложение). С. 94–96.

[25] Plavinskiy SL, Barinova AN, Ozolinya LА. Adverse outcomes of using hormonal drugs. An analysis of pharmacoepidemiological research works and spontaneous reporting databases. Gynecology, Obstetrics and Perinatology. 2019;18(6):92–99. (In Russ). doi: 10.20953/1726-1678-2019-6-92-99

[26] Плавинский С.Л., Баринова А.Н., Озолиня Л.А. Неблагоприятные исходы применения гормональных препаратов. Анализ фармакоэпидемиологических исследований и баз спонтанных отчётов // Вопросы гинекологии, акушерства и перинатологии. 2019. Т. 18, № 6. С. 92–99. doi: 10.20953/1726-1678-2019-6-92-99

[27] Gabelova KA, Shabanova NA, Bezhenar VF, Zvartau EE, Akishina YuA. Risks of venous thromboembolic complications in related to combined oral contraceptives. Obstetrics, Gynecology and Reproduction. 2021;15(6):777–787. (In Russ). doi: 10.17749/2313-7347/ob.gyn.rep.2021.207

[28] Габелова К.А., Шабанова Н.А., Беженарь В.Ф., Звартау Э.Э., Акишина Ю.А. Риски венозных тромбоэмболических осложнений при использовании комбинированных оральных контрацептивов // Акушерство, гинекология и репродукция. 2021. Т. 15, № 6. C. 777–787.

[29] Grishenko OV, Bobritskaya VV. The efficacy of hemostasis in gynecological practice. Health of Woman. 2016.10(116):94–97 (In Russ.). doi: 10.15574/HW.2016.116.94

[30] Гришенко О.В., Бобрицкая В.В. Эффективный гемостаз в гинекологической практике // Здоровье женщины HW. 2016. Т. 10, № 116. С. 94–97. doi: 10.15574/HW.2016.116.94

[31] Snitsarenko EN, Yakovets SM, Andrianova NL. Changes in hemostasis against the background of hormonal treatment of endometrial hyperplasia in reproductive age. Proceedings of the International Scientific and Practical Conference «Sovremennye problemy radiatsionnoi meditsiny: ot nauki k praktike»; 2015 April 24; Gomel. P. 157–158. Available from: https://elibrary.ru/item.asp?id=23824788&ysclid=l97ibdmny300734458 (In Russ).

[32] Сницаренко Е.Н., Яковец С.М., Андрианова Н.Л. Изменение гемостаза на фоне гормонального лечения гиперплазии эндометрия в репродуктивном возрасте // Материалы Международной научно-практической конференции «Современные проблемы радиационной медицины: от науки к практике». Апрель 24, 2015; Гомель. С. 157–158. Режим доступа: https://elibrary.ru/item.asp?id=23824788&ysclid=l97ibdmny300734458. Дата обращения: 13.10.2022.

[33] Ozolinya LA, Patrushev LI, Lutsenko NN, Patrusheva NL. Endometrial hyperplasia: treatment options, prevention of complications, genotype features. Terra Medica. 2013;(3):50–51. (In Russ).

[34] Озолиня Л.А., Патрушев Л.И., Луценко Н.Н., Патрушева Н.Л. Гиперплазия эндометрия: возможности лечения, профилактика осложнений, особенности генотипа // Terra Medica. 2013. № 3(73). С. 50–51.

[35] Lapina IA, Dobrokhotova YuE, Ozolinya LA, Chirvon TG, Taranov VV. An integrated approach to the management of patients with endometrial hyperplasia and metabolic syndrome. Gynecology. 2021;23(1):55–61. (In Russ). doi: 10.26442/20795696.2021.1.200642

[36] Лапина И.А., Доброхотова Ю.Э., Озолиня Л.А., Чирвон Т.Г., Таранов В.В. Комплексный подход к ведению пациенток с гиперплазией эндометрия и метаболическим синдромом // Гинекология. 2021. Т. 23, № 1. С. 55–61. doi: 10.26442/20795696.2021.1.200642

[37] Seregina PE, Totchiev GF, Panova EA. Prognostic significance of PLA polymorphysm of glicoprotein IIIA gene (GPIIIA) in endometrial hyperplasia. RUDN Journal of Medicine. 2009;(5):154–160. (In Russ).

[38] Серегина П.Е., Тотчиев Г.Ф., Панова Е.А. Прогностическая значимость аллелей PLA1/A2 гена гликопротеида GPIIIa при гиперпластических процессах эндометрия // Вестник РУДН. Серия: Медицина. 2009. № 5. С. 154–160.

RIGHTS & PERMISSIONS

Ozolinya L.A., Anikeeva A.A.